Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Eisai to Establish New Parenteral Plant to Manufacture Methycobal in China
May 1, 2013
- With Mucosta Pursuing Diquas, New Drugs Have Growing Presence in Market for Dry Eye Treatments
April 30, 2013
- UMN to Open Japan’s Biggest Biopharmaceutical Contract Manufacturing Facility; Success or Failure Could Determine the Future of this Business in Japan
April 30, 2013
- Ethical Drug Production to Exceed 12 Trillion Yen in 2020: Yano Research Institute
April 30, 2013
- Sandoz K.K. Applies for Gran Biosimilar
April 26, 2013
- Daiichi Sankyo Begins Nimotuzumab PIII Trials for Lung and Gastric Cancers
April 26, 2013
- Boehringer Filed NDA for Afatinib in Japan: Chairman
April 26, 2013
- Takeda Files NDA for Fixed-Dose Combination of Azilva/Amlodipine in Japan
April 26, 2013
- Edoxaban Will Be Key to Achieving Targets in Daiichi Sankyo’s New 5-Year Business Plan
April 26, 2013
- Takeda Initiates Voluntary Partial Recall for Azilva due to Incorrect Expiry Date on Packaging Carton
April 25, 2013
- GSK Files NDA for LAMA/LABA Combination Drug for COPD Treatment
April 24, 2013
- Shionogi Revises Profit Forecasts for FY2012
April 24, 2013
- AnGes MG’s CIN Therapeutic Vaccine Demonstrates Increased Efficacy in Combination with Kampo Medicine
April 24, 2013
- Merck Serono to Launch New Gonalef Pen Devices Starting in May
April 24, 2013
- Ibandronate Injection Non-Inferior to Risedronate: Chugai, Taisho
April 23, 2013
- Nichi-Iko to Launch Allegra AG in June, Says Identical with Original
April 23, 2013
- Daiichi Sankyo Launches Silodosin in China
April 23, 2013
- Ono Pharmaceutical Obtains Exclusive Rights for Once-Daily Wearing-Off Treatment
April 22, 2013
- Pfizer-Mylan Pair’s Japan Generic Share at 2.8%, Aspire for Bigger Slice of Market
April 22, 2013
- Taisho Files SGLT-2 Inhibitor Luseogliflozin, Submits RMP
April 22, 2013
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…